Acute Respiratory Distress Syndrome (ARDS) Clinical Trial
Official title:
STratification AND Outcome of Patients With the Acute Respiratory Distress Syndrome
The American-European Consensus Conference (AECC) and the Berlin definitions of the Acute Respiratory Distress Syndrome (ARDS) could be adequate for epidemiologic studies, but it is not adequate for inclusion of patients into therapeutic clinical trials. Despite recent reports on the effects of standardized ventilator settings on PaO2/FIO2 and fulfillment of AECC and Berlin definitions of ARDS, it is still a matter of debate whether the assessment of hypoxemia at 24 hours is the most appropriate tool for stratifying lung severity in patients with ARDS. The investigators will perform an observational, multicenter, prospective audit in a network of intensive care units in Spain and China for validating and confirming that the assessment of hypoxemia at 24 hours after ARDS onset is the most valuable tool for stratifying and predicting outcome in patients with ARDS.
In 1994, the American-European Consensus Conference (AECC) defined ARDS as follows: 1) acute
and sudden onset of severe respiratory distress, 2) bilateral infiltrates on frontal chest
radiograph, 3) absence of left atrial hypertension or no clinical signs of left heart
failure, and 4) severe hypoxemia, as PaO2/FiO2 ratio <200 mmHg, regardless of FIO2 or PEEP
levels. Although this definition could be adequate for epidemiologic studies, it is not
adequate for inclusion of patients into therapeutic clinical trials. In 2012, a proposal for
updating the ARDS definition (the Berlin criteria) was published and an empirical
classification was proposed according to three PaO2/FiO2 cut-off values at ARDS onset: severe
(≤100 mmHg), moderate (>100-≤200), and mild (>200-≤300) on PEEP≥5 cmH2O. However, despite
that there is sufficient evidence about the interactions between PEEP and FiO2, the Berlin
criteria did not mandate the assessment of hypoxemia at 24 hours under standarized
guidelines.
The PaO2/FIO2 can be easily manipulated. Alterations in PEEP and FIO2 can dramatically change
the PaO2/FIO2. Despite recent reports on the effects of standardized ventilator settings on
PaO2/FIO2 and fulfillment of AECC definitions of ARDS, it is still a matter of debate whether
the assessment of hypoxemia at 24 hours is the most appropriate tool for stratifying lung
severity in patients with ARDS.
The investigators will examine whether the assessment of hypoxemia at 24 h after ARDS
diagnosis under standard guidelines for ventilatory management have an impact on the
stratification of lung severity and on predicting mortality of ARDS patients in the intensive
care unit.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03909854 -
Pragmatic Investigation of Volume Targeted Ventilation-1
|
N/A | |
Recruiting |
NCT02637011 -
Surviving ARDS: The Influence of Quality of Care and Individual Patient Characteristics on Quality of Life
|
N/A | |
Recruiting |
NCT02574169 -
Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation
|
N/A | |
Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
Terminated |
NCT04511650 -
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
|
Phase 2 | |
Completed |
NCT05024500 -
Clinical and Functional Outcomes of Critically Ill Patients With COVID-19
|
N/A | |
Recruiting |
NCT01339533 -
Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation
|
Phase 2 | |
Active, not recruiting |
NCT01274260 -
Trial of Steroids in Pediatric Acute Lung Injury/ARDS
|
Phase 2 | |
Recruiting |
NCT03296059 -
Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates
|
N/A | |
Terminated |
NCT04609865 -
Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
|
Phase 3 | |
Active, not recruiting |
NCT04009330 -
Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome
|
||
Not yet recruiting |
NCT05847517 -
Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN)
|
Phase 3 | |
Not yet recruiting |
NCT06127381 -
An Open-label Study of the Safety and Pharmacokinetics of the TGKP
|
Phase 1 | |
Completed |
NCT01854424 -
Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS
|
N/A | |
Completed |
NCT03870009 -
Validation of a Semi-automatized Method to Detect Cyclic Hyperinflation on CT-scan in ARDS
|
N/A | |
Completed |
NCT04311697 -
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
|
Phase 2/Phase 3 | |
Recruiting |
NCT02095444 -
Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection
|
Phase 1/Phase 2 | |
Recruiting |
NCT04460859 -
RecruitmEnt Assessed by eleCtRical Impedance Tomography
|
||
Completed |
NCT01926093 -
Low Dose Lung CT Scan for Quantitative Analysis in ARDS Patients
|
N/A | |
Terminated |
NCT01506401 -
The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial
|
Phase 3 |